Q4 2024 Gerresheimer AG Earnings Call Transcript

Feb 26, 2025 / 09:00AM GMT

Release Date Price: $82.43

Transcript

Key Points

Positve

Gerresheimer AG (GRRMY) achieved an organic revenue growth of 5.4% in Q4 2024, driven by increased demand for vials and systems for biologics.
The company successfully completed the acquisition of Bormioli Pharma, which is expected to grow revenues by approximately 15% to 20% and be margin accretive in 2025.
Gerresheimer AG (GRRMY) increased the revenue share of systems and solutions for biologics from 11% in 2023 to 15% in 2024, indicating a successful strategic transformation.
The FDA granted tentative approval for the SQ Innovation Lasix ONYU, showcasing Gerresheimer AG (GRRMY)'s expertise in innovative drug delivery solutions.
The company reported a strong cash flow performance in Q4 2024, with free cash flow before M&A almost on par with the previous year.

Negative

Full-year organic revenue growth was only 2.9%, with adjusted EBITDA growth at 4.1%, reflecting a slower-than-expected recovery from market destocking.
Gerresheimer AG (GRRMY) issued a profit warning in September 2024, the first since 2009, due to unusual market developments.
The FDA's tentative approval for the SQ Innovation Lasix ONYU means the product cannot be marketed until October 2025, delaying revenue contributions.
The company's molded glass cosmetics segment underperformed due to a softening in consumer spending on cosmetic products.
Gerresheimer AG (GRRMY) faces a high leverage ratio of 3.7 times following the Bormioli acquisition, with plans to reduce it to mid-3s by year-end.

Operator

Ladies and gentlemen, welcome to the publication Q4 and full year 2024 results conference call. I am Vicky, the Chorus Call operator. I would like to remind you that all participants will be in listen-only mode and the conference is being recorded. (Operator Instructions) The conference must not be recorded for publication or broadcast.

At this time, it is my pleasure to hand over to Guido Pickert , Vice President of Corporate Investor Relations. Please go ahead, sir.

Guido Pickert

Gerresheimer AG - Vice President - Corporate Investor Relations

Thank you very much, Vicky. Good morning, everyone, and thank you for joining today's call. I will now hand over to our CEO, Dietmar Siemssen, to run you through the highlights of the quarter and full year together with our CFO, Dr. Bernd Metzner. Dietmar?

Dietmar Siemssen

Gerresheimer AG - Chairman of the Management Board, Chief Executive Officer

Good morning. Welcome, everybody. Thank you for joining us this morning.

For those who are new to the call,

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.